An experimental treatment may offer hope in slowing the progression of dementia for patients with a rare genetic form of Alzheimer’s disease, according to new findings. The drug, designed to target amyloid plaques, aims to reduce the risk of cognitive decline years before symptoms appear.
In a study involving 22 participants with genetic mutations that lead to excessive amyloid production in the brain, researchers observed promising results. Amyloid plaques, which form when amyloid protein clumps together, are a hallmark of Alzheimer’s disease and typically accumulate long before cognitive symptoms develop.
The study, published in Lancet Neurology, explored the effects of gantenerumab, an anti-amyloid drug, on these patients over an eight-year period. By the end of the treatment, the risk of developing Alzheimer’s symptoms was halved, dropping from 100% to around 50%.
“As everyone in this study was genetically predisposed to develop Alzheimer’s disease, the fact that some participants remain symptom-free is promising,” explained Dr. Randall Bateman, professor of neurology at Washington University School of Medicine and co-author of the study. “We’ve continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all.”
Early Intervention May Delay Onset of Symptoms
The findings suggest that early intervention with anti-amyloid drugs could play a critical role in delaying or even preventing the onset of Alzheimer’s disease. However, the study also revealed that the effectiveness of the treatment depends on the duration of use. Patients who received gantenerumab for eight years showed significant cognitive preservation, while those treated for only two to three years did not experience noticeable improvement.
This highlights the importance of extended treatment, with years of medication potentially being required to effectively delay symptoms. The results emphasize the need for preventive therapies to be started as early as possible in genetically at-risk individuals.
Limitations and Future Research Directions
While the results are encouraging, experts caution that the study’s limitations should be considered. Dr. Charles Marshall, professor of clinical neurology at Queen Mary University of London, noted that the study’s small sample size and its secondary evaluation design make the findings less definitive. “The results are exciting but less certain due to the study’s limited scope,” he said.
Additionally, Dr. Marshall pointed out that gantenerumab may not be as effective as other amyloid-reducing treatments currently available, which suggests that newer therapies could yield even better outcomes.
It is important to note that gantenerumab was discontinued in 2022 after it failed to show significant effects on the more common forms of Alzheimer’s in a larger study involving over 1,900 participants. This highlights the complexity of Alzheimer’s disease and the need for continued research.
The Need for Ongoing Research
Further research is needed to determine the potential of anti-amyloid drugs in treating non-genetic forms of Alzheimer’s and to identify the most effective treatment duration. Additionally, studies must evaluate the safety profiles of these drugs, as some have been linked to brain abnormalities and localized swelling on scans. While these side effects generally resolve on their own, in some cases, they can become serious.
In the current study, two participants were forced to stop the treatment due to side effects, though none of the adverse effects were life-threatening. Researchers emphasized that continued evaluation of anti-amyloid drugs will be crucial for understanding their long-term effects and safety in broader patient populations.
Related topics:
- Excessive Sleepiness In Older Adults: A Possible Indicator Of Dementia Risk?
- Study Suggests Long-Term Pain Reliever Use May Help Lower Dementia Risk For Some Individuals
- Better Cardiovascular Health Linked To Slower Cognitive Decline And Lower Dementia Risk
